NASDAQ:BNR Burning Rock Biotech (BNR) Stock Price, News & Analysis $2.80 -0.10 (-3.45%) Closing price 03:56 PM EasternExtended Trading$2.82 +0.02 (+0.54%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Burning Rock Biotech Stock (NASDAQ:BNR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Burning Rock Biotech alerts:Sign Up Key Stats Today's Range$2.80▼$2.9450-Day Range$2.90▼$7.9052-Week Range$2.62▼$8.99Volume11,668 shsAverage Volume15,022 shsMarket Capitalization$28.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBurning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.Read More… Remove Ads Burning Rock Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreBNR MarketRank™: Burning Rock Biotech scored higher than 21% of companies evaluated by MarketBeat, and ranked 277th out of 321 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Burning Rock Biotech. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Burning Rock Biotech is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Burning Rock Biotech is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBurning Rock Biotech has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Burning Rock Biotech's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.56% of the float of Burning Rock Biotech has been sold short.Short Interest Ratio / Days to CoverBurning Rock Biotech has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Burning Rock Biotech has recently decreased by 2.14%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBurning Rock Biotech does not currently pay a dividend.Dividend GrowthBurning Rock Biotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.56% of the float of Burning Rock Biotech has been sold short.Short Interest Ratio / Days to CoverBurning Rock Biotech has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Burning Rock Biotech has recently decreased by 2.14%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News SentimentN/A News SentimentBurning Rock Biotech has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Business Services companies.Search Interest1 people have searched for BNR on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Burning Rock Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders30.30% of the stock of Burning Rock Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.03% of the stock of Burning Rock Biotech is held by institutions.Read more about Burning Rock Biotech's insider trading history. Receive BNR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Burning Rock Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address BNR Stock News HeadlinesBurning Rock Biotech Limited Reports Fourth Quarter and Full Year 2024 Financial Results, Highlighting Progress Towards ProfitabilityMarch 25, 2025 | quiverquant.comBurning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial ResultsMarch 25, 2025 | globenewswire.comGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.April 17, 2025 | Weiss Ratings (Ad)Burning Rock Announces Results of 2024 Annual General MeetingDecember 31, 2024 | globenewswire.comBurning Rock Biotech’s Strategic Growth and Financial ResultsDecember 4, 2024 | markets.businessinsider.comBurning Rock Biotech Limited Reports Q3 2024 Financial Results and Strategic Developments in Precision OncologyDecember 4, 2024 | quiverquant.comBurning Rock Biotech Schedules AGM for December 2024December 4, 2024 | markets.businessinsider.comBurning Rock Reports Third Quarter 2024 Financial ResultsDecember 3, 2024 | globenewswire.comSee More Headlines BNR Stock Analysis - Frequently Asked Questions How have BNR shares performed this year? Burning Rock Biotech's stock was trading at $6.75 on January 1st, 2025. Since then, BNR stock has decreased by 58.1% and is now trading at $2.8250. View the best growth stocks for 2025 here. How were Burning Rock Biotech's earnings last quarter? Burning Rock Biotech Limited (NASDAQ:BNR) posted its quarterly earnings data on Tuesday, March, 25th. The company reported ($1.08) earnings per share for the quarter, topping the consensus estimate of ($1.40) by $0.32. The firm had revenue of $17.27 million for the quarter. Burning Rock Biotech had a negative trailing twelve-month return on equity of 60.68% and a negative net margin of 83.50%. When did Burning Rock Biotech's stock split? Burning Rock Biotech shares reverse split on Wednesday, May 15th 2024. The 1-10 reverse split was announced on Wednesday, May 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Burning Rock Biotech IPO? Burning Rock Biotech (BNR) raised $196 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 13,500,000 shares at a price of $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen served as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers. How do I buy shares of Burning Rock Biotech? Shares of BNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Burning Rock Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Burning Rock Biotech investors own include Tesla (TSLA), NVIDIA (NVDA), Intel (INTC), Vertex Pharmaceuticals (VRTX), HubSpot (HUBS), NIO (NIO) and Alibaba Group (BABA). Company Calendar Last Earnings3/25/2025Today4/17/2025Next Earnings (Estimated)6/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:BNR CIK1792267 Webwww.brbiotech.com Phone86-185-0164-1666FaxN/AEmployees1,390Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,070,000.00 Net Margins-83.50% Pretax Margin-83.40% Return on Equity-60.68% Return on Assets-42.30% Debt Debt-to-Equity RatioN/A Current Ratio3.04 Quick Ratio2.78 Sales & Book Value Annual Sales$515.82 million Price / Sales0.06 Cash FlowN/A Price / Cash FlowN/A Book Value$10.56 per share Price / Book0.27Miscellaneous Outstanding Shares10,244,000Free Float7,140,000Market Cap$29.71 million OptionableNot Optionable Beta0.67 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:BNR) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Burning Rock Biotech Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Burning Rock Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.